Arnold and Hilgartner review pathogenesis and surgical management of hemophilic arthropathy based on 169 patients at Hospital for Special Surgery. The paper establishes a five-stage radiographic classification with direct treatment implications and specifies perioperative factor replacement protocols. It covers the full spectrum from acute hemarthrosis through synovectomy, osteotomy, and total joint replacement.
Before lyophilized factor concentrates, adequate replacement therapy caused circulatory overload and elective surgery was impossible. This paper arrived just as concentrates made surgical correction feasible, and it immediately established the framework — classification, dosing protocol, and surgical indications. That structured how hemophilic arthropathy has been managed ever since.
When you see a hemophilic patient with subchondral cysts and patellar squaring but a preserved cartilage space on radiograph, that is Stage III. Act now. Synovectomy at Stage III can halt progression. Waiting until Stage IV means the cartilage is already gone and reconstruction is your only option.
For any elective procedure, screen for inhibitors first, run a survival study to establish that specific product's half-life in that patient, then dose to 100% at incision. The tiered postoperative protocol (>60% / >40% / 20%) maps to the biological phases of wound healing and rehabilitation stress. It is not arbitrary.
The enzymatic data carry a practical warning: pain relief after factor infusion does not mean the joint is safe. The synovium is still producing cathepsin D. Controlling each bleeding episode early. Ideally at home within minutes of onset. Is what prevents the enzymatic cascade from destroying cartilage over time.
Arnold and Hilgartner review pathogenesis and surgical management of hemophilic arthropathy based on 169 patients at Hospital for Special Surgery. The paper establishes a five-stage radiographic classification with direct treatment implications and specifies perioperative factor replacement protocols. It covers the full spectrum from acute hemarthrosis through synovectomy, osteotomy, and total joint replacement.
Before lyophilized factor concentrates, adequate replacement therapy caused circulatory overload and elective surgery was impossible. This paper arrived just as concentrates made surgical correction feasible, and it immediately established the framework — classification, dosing protocol, and surgical indications. That structured how hemophilic arthropathy has been managed ever since.
When you see a hemophilic patient with subchondral cysts and patellar squaring but a preserved cartilage space on radiograph, that is Stage III. Act now. Synovectomy at Stage III can halt progression. Waiting until Stage IV means the cartilage is already gone and reconstruction is your only option.
For any elective procedure, screen for inhibitors first, run a survival study to establish that specific product's half-life in that patient, then dose to 100% at incision. The tiered postoperative protocol (>60% / >40% / 20%) maps to the biological phases of wound healing and rehabilitation stress. It is not arbitrary.
The enzymatic data carry a practical warning: pain relief after factor infusion does not mean the joint is safe. The synovium is still producing cathepsin D. Controlling each bleeding episode early. Ideally at home within minutes of onset. Is what prevents the enzymatic cascade from destroying cartilage over time.